GSK Files Its BCMA Drug In Multiple Myeloma
Filing Underpinned By Good DREAMM-2 results
GSK has filed its anti-BCMA agent with the FDA after full Phase II DREAMM-2 data showed an overall response rate of 31% in patients with heavily pre-treated multiple myeloma.
You may also be interested in...
The European Medicines Agency is this week deciding whether GlaxoSmithKline’s planned EU marketing application for its BCMA-targeting therapy merits an accelerated assessment.
Confirmation of good trial data for GSK's promising anti-BCMA antibody-drug conjugate GSK2857916 in multiple myeloma patients keeps it in the running for eventual regulatory approval by 2020 - but it faces a formidable field of emerging rival therapies.
AstraZeneca has vowed to slash its carbon emissions to zero by 2025 and ensure its entire value chain is carbon negative by 2030. It will spend up to $1bn to do so.